Clinical and molecular aspects of breast cancer: Targets and therapies
- PMID: 29945114
- DOI: 10.1016/j.biopha.2018.06.066
Clinical and molecular aspects of breast cancer: Targets and therapies
Abstract
Breast Cancer is a complex disease characterized by the occurrence of multiple molecular alterations. Currently, some molecular markers are in use for breast cancer diagnostic, prognostic, and predictive purposes. Thus, genetic signatures are available for improving the decision-making. The biomarkers are also essential as therapeutic approaches, but many questions remain due to the lack of efficacy on breast cancer treatment, mainly for triple-negative breast cancer subtype. Since the genetic profile of breast cancer can also be related to different ethnic groups and geographic areas, the reference populations of the genetic assays and clinical trials need to include a broader population beyond the European and North American patients. In this review, we analyzed the current and potential molecular markers that could help to improve the strategies for breast cancer therapy.
Keywords: Biological markers; Breast cancer; Molecular targeted therapy.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3. Lancet Oncol. 2015. PMID: 26342236 Clinical Trial.
-
Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.Eur J Cancer. 2017 Oct;84:270-277. doi: 10.1016/j.ejca.2017.07.042. Epub 2017 Aug 24. Eur J Cancer. 2017. PMID: 28844015
-
Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.Cancer Lett. 2015 Jul 10;363(1):1-6. doi: 10.1016/j.canlet.2015.04.009. Epub 2015 Apr 15. Cancer Lett. 2015. PMID: 25890222 Free PMC article. Review.
-
The Evolving Landscape of HER2 Targeting in Breast Cancer.JAMA Oncol. 2015 Nov;1(8):1154-61. doi: 10.1001/jamaoncol.2015.2286. JAMA Oncol. 2015. PMID: 26204261 Review.
-
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.World J Gastroenterol. 2016 Jan 14;22(2):776-89. doi: 10.3748/wjg.v22.i2.776. World J Gastroenterol. 2016. PMID: 26811624 Free PMC article. Review.
Cited by
-
In-Silico Characterization of Estrogen Reactivating β-Glucuronidase Enzyme in GIT Associated Microbiota of Normal Human and Breast Cancer Patients.Genes (Basel). 2022 Aug 27;13(9):1545. doi: 10.3390/genes13091545. Genes (Basel). 2022. PMID: 36140713 Free PMC article.
-
Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems.Pharmaceutics. 2019 Jan 8;11(1):22. doi: 10.3390/pharmaceutics11010022. Pharmaceutics. 2019. PMID: 30625999 Free PMC article. Review.
-
Labdane Diterpenoids from Leonotis ocymifolia with Selective Cytotoxic Activity Against HCC70 Breast Cancer Cell Line.Diseases. 2025 May 1;13(5):140. doi: 10.3390/diseases13050140. Diseases. 2025. PMID: 40422572 Free PMC article.
-
Synthesis, Characterisation and Mechanism of Action of Anticancer 3-Fluoroazetidin-2-ones.Pharmaceuticals (Basel). 2022 Aug 24;15(9):1044. doi: 10.3390/ph15091044. Pharmaceuticals (Basel). 2022. PMID: 36145265 Free PMC article.
-
Identification of modules and functional analysis in CRC subtypes by integrated bioinformatics analysis.PLoS One. 2019 Aug 30;14(8):e0221772. doi: 10.1371/journal.pone.0221772. eCollection 2019. PLoS One. 2019. PMID: 31469863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical